Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax
| Status: | Completed |
|---|---|
| Conditions: | Rheumatology |
| Therapuetic Areas: | Rheumatology |
| Healthy: | No |
| Age Range: | 50 - 70 |
| Updated: | 4/21/2016 |
| Start Date: | April 2014 |
| End Date: | August 2015 |
Evaluation of Ocular Surface Inflammatory Mediators and Ocular Surface Metrology Effected by Lotemax
The purpose of this study is to evaluate the effects of an anti-inflammatory drug (Lotemax®)
on the surface of the eye and tear film (a film that coats the eye which is made up of oil
and water).
on the surface of the eye and tear film (a film that coats the eye which is made up of oil
and water).
INCLUSION CRITERIA:
- Age 50-70
- Diagnosed with Sjogren's Disease
- Good general health (defined by medication use that has not changed within the last 2
months and the absence of medical conditions that are deemed confounding to the data
as determined by the PI)
- Ability to give informed consent
- Willing to spend time for the study; approximately one hour for a screening visit and
between 60-90 minutes for each of the measurement visits
- Either gender
- Any racial or ethnic origin
EXCLUSION CRITERIA:
- Use of any prescription ocular medication (such as but not limited to, glaucoma
medications and Restasis) used within 14 days of the screening visit or started prior
to the measurement visit(s).
- Current acute eye disease that affects the surface of the eye such as, but not
limited to blepharitis, ocular allergy, and infection.
- Subjects who have had cataract surgery less than one year ago
- Use of soft or hard contact lenses.
- Female subjects may not be pregnant or lactating (subjects will be asked to
self-report these conditions).
- Inability to provide analyzable data
We found this trial at
1
site
Click here to add this to my saved trials
